BRISBANE, Australia & CARLSBAD, Calif.--(BUSINESS WIRE)--ImpediMed Limited (ASX:IPD), a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status using bioimpedance spectroscopy (BIS), is pleased to announce the initial educational webinar in an series presented by Sheila Ridner Ph.D., RN, FAAN, MSN, MSHSA, BSN, principal investigator of the PREVENT trial and the Martha Rivers Ingram Professor of Nursing at Vanderbilt University School of Nursing. The presentation proposed a new standard of care for health care providers and health plans that is aligned with the transition to value-based reimbursement.
“With millions of health plan members impacted by a breast cancer diagnosis, the PREVENT trial provides managed care physicians and decision-makers with the clinical, third-party evidence they need to make L-Dex the standard of care for monitoring patients at risk of developing lymphedema,” says Richard Carreon, managing director and CEO, ImpediMed. “Authors from the PREVENT trial also determined that L-Dex is very sensitive in the assessment of sub-clinical lymphedema in patients with a history of breast cancer. The published study will be used as part of our submission to the National Comprehensive Cancer Network (NCCN) guidelines to establish BIS as the standard of care for monitoring patients at risk of developing lymphedema.”
The PREVENT study also supports the recommendation for an aggressive measurement protocol consisting of an L-Dex assessment every three months, especially during the first 6-12 months post-surgery to facilitate identification of sub-clinical lymphedema.
“We were extremely gratified with the content of the webinar, “Removing the Mystery Around Bioimpedance-Moving Towards a New Standard of Care,” continues Carreon. “Dr. Ridner was very clear that SOZO with L-Dex can be seamlessly integrated into the busy practice of a primary care provider and performed quickly and easily by a medical assistant. This optimizes physician schedules and maximizes the resources of support staff.”
About ImpediMed
Founded and headquartered in Brisbane, Australia, with U.S. and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status. ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications, including heart failure and lymphedema, sold in select markets globally. Visit www.impedimed.com.
